73307-36-5

Upstream product

• 67039-85-4 2-oxo-7-syn-<3αβ-hydroxy-4-(3-chlorophenoxy)-1-trans-butenyl>-8-anti-hydroxy-cis-bicyclo<4.3.0>nonan-3-ol 
• 67039-82-1 2-syn-(3-methoxy-trans,cis-propenyl)-3-anti-<3αβ-(tetrahydropyran-2-yloxy)-4-(3-chlorophenoxy)-1-trans-butenyl>-4-syn-(tetrahydropyran-2-yloxy)cyclopentan-1-ol 
• 67039-87-6 1-syn,4-syn-bis(tetrahydropyran-2-yloxy)-2-syn-(2-carbomethoxyethyl)-3-anti-<3αβ-(tetrahydrppyran-2-yloxy)-4-(3-chlorophenoxy)-1-trans-butenyl>cyclopentane 
• 67039-94-5 1-syn,4-syn-bis(tetrahydropyran-2-yloxy)-2-syn-(2-formyl-1-trans-ethenyl)-3-anti-<3αβ-(tetrahydropyran-2-yloxy)-4-(3-chlorophenoxy)-1-trans-butenyl>cyclopentane 
• 67039-93-4 (E)-3-[(1R,2R,3R,5S)-2-[(E)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-prop-2-en-1-ol 
• 67039-86-5 3-{(1R,2R,3R,5S)-2-[(E)-4-(3-Chloro-phenoxy)-3-hydroxy-but-1-enyl]-3,5-dihydroxy-cyclopentyl}-propionic acid methyl ester 
• 73319-03-6 3-{(1R,2R,3R,5S)-2-[(E)-4-(3-Chloro-phenoxy)-3-hydroxy-but-1-enyl]-3,5-dihydroxy-cyclopentyl}-propionic acid 
• 67039-95-6 (2E,4E,6E)-7-[(1R,2R,3R,5S)-2-[(E)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-hepta-2,4,6-trienoic acid methyl ester 
• 67039-91-2 1-syn,4-syn-bis(tetrahydropyran-2-yloxy)-2-syn-<2-carbomethoxy-2-(phenylselenyl)ethyl>-3-anti-<3αβ-(tetrahydrppyran-2-yloxy)-4-(3-chlorophenoxy)-1-trans-butenyl>cyclopentane 
• 67039-92-3 (E)-3-[(1R,2R,3R,5S)-2-[(E)-4-(3-Chloro-phenoxy)-3-(tetrahydro-pyran-2-yloxy)-but-1-enyl]-3,5-bis-(tetrahydro-pyran-2-yloxy)-cyclopentyl]-acrylic acid methyl ester 

Relevant academic research and scientific papers

Prostaglandin Analogues Possessing Antinidatory Effects. 2. Modification of the α Chain

Additional double bonds were introduced into the α chain in 16-phenoxy-, 16-(3-chlorophenoxy)-, 16--, and 16-(4-chlorophenoxy)-17,18,19,20-tetranorprostaglandins which have antinidatory effects.Of these analogues, the Δ3/